- Conditions
- Recurrent Melanoma, Stage IV Melanoma
- Interventions
- Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Melanoma (Skin)
- Interventions
- semaxanib, thalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Melanoma
- Interventions
- RFT5pdgA
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma (Skin)
- Interventions
- gp100 antigen, incomplete Freund's adjuvant, keyhole limpet hemocyanin, fludarabine phosphate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Providence Cancer Center, Earle A. Chiles Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Interventions
- tyrosinase peptide, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Malignant Melanoma
- Interventions
- imexon, DTIC
- Drug
- Lead sponsor
- AmpliMed Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
- Conditions
- Melanoma
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Hartford, Connecticut • Minneapolis, Minnesota • Charlotte, North Carolina + 1 more
- Conditions
- Melanoma
- Interventions
- Montanide ISA 51
- Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Melanoma (Skin)
- Interventions
- recombinant interferon alfa-2b, azacitidine
- Biological · Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Melanoma of the Skin, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer
- Interventions
- Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, TLR8 Agonist VTX-2337
- Drug · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
- Interventions
- VET3-TGI, Atezolizumab
- Drug
- Lead sponsor
- KaliVir Immunotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Orange, California • Miami, Florida + 4 more
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Best Practice, Biospecimen Collection, Computed Tomography, Dietary Intervention, Educational Activity, Glucose Measurement, Ketone Measurement, Questionnaire Administration
- Other · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma
- Interventions
- Pazopanib and Paclitaxel
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
- Interventions
- ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis
- Biological · Radiation · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Malignant Melanoma
- Interventions
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Drug
- Lead sponsor
- Northern California Melanoma Center
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Melanoma (Skin)
- Interventions
- MART-1 antigen, IL-2, gp100 antigen, GM-CSF, MART-1a peptide
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Melanoma (Skin)
- Interventions
- recombinant vaccinia-TRICOM vaccine
- Biological
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Riluzole, Sorafenib Tosylate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Melanoma
- Interventions
- Entinostat, Pembrolizumab
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Melanoma (Skin)
- Interventions
- NY-ESO-1 peptide vaccine, aldesleukin, filgrastim, incomplete Freund's adjuvant, therapeutic autologous lymphocytes, cyclophosphamide, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, Cervical Carcinosarcoma, Cervical Squamous Cell Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Unresectable Melanoma, Uterine Corpus Carcinosarcoma
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study
- Biological · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more